Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) will chair the plenary session titled, “Drugs Targeting Adenosine Receptors,” at the 2016 Keystone Symposia J5 in Vancouver, Canada on Jan. 24-28.
This year’s Purinergic Signaling symposium is a joint session with Keystone Symposia J6 Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies. The conference will focus on the leading developments in purinergic receptors, including the A3 adenosine receptor (A3AR) in the treatment of cancer.
Dr. Fishman will also deliver a scientific presentation titled, “Utilizing the A3 Adenosine Receptor as a Target to Combat Cancer: From Lab to Labeling.”
Can-Fite’s drug candidate CF102, an A3AR agonist, is currently being evaluated in a global Phase 2 trial for the treatment of hepatocellular carcinoma, the most common form of liver cancer.
“There is growing body of knowledge on the role that A3AR plays in a wide range of medical conditions, from cancer to autoimmune diseases,” Dr. Fishman said. “Can-Fite is a leader in the development of drugs targeting A3AR and we hold a substantial intellectual property portfolio in this space.”
